Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 8/20 | 0.67 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12064790 | 1.00 | PSEN1 (0.67) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL635099 | 1.00 | PSEN1 (0.67) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL13084628 | 1.00 | PSEN1 (0.67) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL627937 | 0.97 | PSEN1 (0.66) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL627615 | 0.94 | PSEN1 (0.64) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL12064998 | 0.90 | PSEN1 (0.66) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL635093 | 0.88 | PSEN1 (0.54) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL635737 | 0.88 | PSEN1 (0.54) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL635293 | 0.88 | PSEN1 (0.54) | PSEN1GSTO1PTPN1MEN1KMT2A | |
| SCHEMBL635369 | 0.88 | PSEN1 (0.54) | PSEN1GSTO1PTPN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461362-B2 | Protein phosphatase 2A-activating agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-06-11 | — | — | US | disclosed |
| US-8362071-B2 | Antiadhesion agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362071-B2 | Antiadhesion agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2419414-A1 | PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS | The Ohio State University Research Foundation (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100267820-A1 | ANTIADHESION AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267820-A1 | ANTIADHESION AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267673-A1 | PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS | THE OHIO SATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010120711-A1 | PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267673-A1 | PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS | PPP2CA, PPP2R2A, PPP2R1A | PSEN1 1965/4885GSTO1 251/4885PTPN1 386/4885 |
| US-20100267820-A1 | ANTIADHESION AGENTS | SELE, EPCAM, SELP | PSEN1 3830/4885GSTO1 80/4885PTPN1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.